James Wooldridge
Hoofd Techniek/Wetenschap/O&O bij CHECKMATE PHARMACEUTICALS, INC.
Profiel
James Wooldridge is currently the Chief Medical Officer at Checkmate Pharmaceuticals, Inc. He previously worked as the Chief Medical Officer at Spyre Therapeutics, Inc. from 2017 to 2019 and as the Chief Scientific Officer at Eli Lilly & Co. He received his doctorate degree from Tulane University in 1992 and his undergraduate degree from William Jewell College in 1988.
Actieve functies van James Wooldridge
| Bedrijven | Functie | Begin |
|---|---|---|
| CHECKMATE PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-10-2019 |
Eerdere bekende functies van James Wooldridge
| Bedrijven | Functie | Einde |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 10-10-2019 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Opleiding van James Wooldridge
| William Jewell College | Undergraduate Degree |
| Tulane University (Louisiana) | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
